172 related articles for article (PubMed ID: 18623220)
1. MRI abnormalities in infants with sickle cell anemia-indication for preemptive therapy?
Ozsahin H
Pediatr Blood Cancer; 2008 Nov; 51(5):573-4. PubMed ID: 18623220
[No Abstract] [Full Text] [Related]
2. Hydroxyurea as secondary prevention for stroke in children with sickle cell anemia.
DeBaun MR
J Pediatr; 2005 Oct; 147(4):560-1. PubMed ID: 16227052
[No Abstract] [Full Text] [Related]
3. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
Ware RE; Zimmerman SA; Sylvestre PB; Mortier NA; Davis JS; Treem WR; Schultz WH
J Pediatr; 2004 Sep; 145(3):346-52. PubMed ID: 15343189
[TBL] [Abstract][Full Text] [Related]
4. Expanding the role of hydroxyurea in children with sickle cell disease.
Rogers ZR; Buchanan GR
J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
[No Abstract] [Full Text] [Related]
5. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
Galadanci AA; Galadanci NA; Jibir BW; Abdullahi SU; Idris N; Gambo S; Ali Abubakar SA; Kabo NA; Bello-Manga H; Haliru L; Bashir I; Aliyu MH; Galadanci JA; DeBaun MR
Am J Hematol; 2019 Nov; 94(11):E305-E307. PubMed ID: 31423630
[No Abstract] [Full Text] [Related]
6. Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis.
Cunningham-Myrie C; Abdulkadri A; Waugh A; Bortolusso Ali S; King LG; Knight-Madden J; Reid M
Pediatr Blood Cancer; 2015 Oct; 62(10):1862-4. PubMed ID: 25929458
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
Anderson N
Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
[TBL] [Abstract][Full Text] [Related]
8. Building capacity to reduce stroke in children with sickle cell anemia in the Dominican Republic: the SACRED trial.
Sánchez LM; Nieves RM; Latham T; Stuber S; Luden JR; Urcuyo GS; Berges ME; Florencio C; Gonzalez C; Del Villar P; Lane A; Schultz W; Jeste N; Mena R; Ware RE
Blood Adv; 2018 Nov; 2(Suppl 1):50-53. PubMed ID: 30504201
[No Abstract] [Full Text] [Related]
9. Sickle cell disease in North Europe.
Howard J; Davies SC
Scand J Clin Lab Invest; 2007; 67(1):27-38. PubMed ID: 17365983
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea for children with sickle cell disease.
Heeney MM; Ware RE
Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
[TBL] [Abstract][Full Text] [Related]
11. Sickle cell disease: What all PAs should know.
Kayinqo G
JAAPA; 2012 Sep; 25(9):19-20. PubMed ID: 22991882
[No Abstract] [Full Text] [Related]
12. Hydroxyurea in very young children with sickle cell anemia is not a cure-all.
Powars DR
J Pediatr; 2001 Dec; 139(6):763-4. PubMed ID: 11743496
[No Abstract] [Full Text] [Related]
13. Hydroxyurea and stroke prevention in sickle cell anaemia: the challenge of application in sub-Saharan Africa.
Diop S; de Montalembert M
Lancet Haematol; 2023 Apr; 10(4):e237-e238. PubMed ID: 36870359
[No Abstract] [Full Text] [Related]
14. Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
Wang WC; Morales KH; Scher CD; Styles L; Olivieri N; Adams R; Brambilla D;
J Pediatr; 2005 Aug; 147(2):244-7. PubMed ID: 16126058
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea and new agents for the treatment of sickle cell disease.
Rodgers GP
Clin Adv Hematol Oncol; 2004 Nov; 2(11):713-5. PubMed ID: 16163257
[No Abstract] [Full Text] [Related]
16. The clinical care of adult patients with sickle cell disease.
Olujohungbe A; Howard J
Br J Hosp Med (Lond); 2008 Nov; 69(11):616-9. PubMed ID: 19069260
[TBL] [Abstract][Full Text] [Related]
17. Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy.
Ballas SK; Martinez U; Savage M
Hemoglobin; 2014; 38(5):373-5. PubMed ID: 25238042
[TBL] [Abstract][Full Text] [Related]
18. Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic.
DeBaun MR
Blood; 2020 May; 135(22):1997-1999. PubMed ID: 32282033
[No Abstract] [Full Text] [Related]
19. Sickle cell disease--pathophysiology and treatment.
Redding-Lallinger R; Knoll C
Curr Probl Pediatr Adolesc Health Care; 2006; 36(10):346-76. PubMed ID: 17055417
[No Abstract] [Full Text] [Related]
20. Hydroxyurea for sickle cell anemia.
Bachmeyer C; Aractingi S; Lionnet F
N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18609755
[No Abstract] [Full Text] [Related]
[Next] [New Search]
